◆ 会议时间:2024年9月28日至10月2日 ◆ 会议地点:美国 休斯顿(Houston, TX) ◆ 下次会议:2025年第75届美国神经外科医师年会/大会(CNS2025) ◆ 会议简介: 2024年美国神经外科医师年会(CNS 2024)将于2024年9月28日至10月2日在美国德克萨斯州休斯顿举行。美国神经外科医师学会年会(CNS年会)是目前世界神经外科领域规模最大、学
◆ 会议时间:2024年9月28日至10月2日 ◆ 会议地点:美国 休斯顿(Houston, TX) ◆ 下次会议:2025年第75届美国神经外科医师年会/大会(CNS2025) ◆ 会议简介: 2024年美国神经外科医师年会(CNS 2024)将于2024年9月28日至10月2日在美国德克萨斯州休斯顿举行。美国神经外科医师学会年会(CNS年会)是目前世界神经外科领...
The CNS Annual Meeting is the premier forum for neurosurgeons, residents, and allied healthcare professionals to gain a competitive edge by sharing best pr. CNS Annual Meeting 2024 is held in (Houston TX), United States, from 9/28/2024 to 9/28/2024 in G
Ramiro Guillen, M.D. completed his psychiatric residency at Menninger Department of Psychiatry and Baylor College of Medicine in Houston, Texas. READ MORE MARILYN PUPO-GUILLEN, M.D. Dr. Pupo-Guillen completed a Bachelors of Arts at the University of Miami and later on obtained her Medical Doct...
FORM 8-K (Current report filing) Filed 08/07/24 for the Period Ending 08/06/24 Address Telephone CIK Symbol SIC Code Industry Sector Fiscal Year 2100 WEST LOOP SOUTH SUITE 900 HOUSTON, TX, 77027 1-800-946-9185 0001729427 CNSP 2834 - Pharmaceutical Preparations Biotechnology & Medical ...
Research workshop: In October 2022, these experts convened in Houston, TX for the Rudi Schulte Research Institute Research Workshop titled “Improving cognitive and psychological outcomes hydrocephalus.” Two plenary sessions consisted of formal presentations by invited speakers. Topics included neuropsychol...
Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TXJulie SimonDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TXAlexander M. MenziesMelanoma Institute Australia, Wollstonecraft, NSW, AustraliaDenai R. ...
clinical pharmaceutical company organized as a Nevada corporation in July 2017 to focus on the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors, based on intellectual property that we license under license agreements with Houston Pharmaceuticals, ...
Presented at: 2024 SNO Annual Meeting; November 21-24, 2024; Houston, TX.Abstract CTNI-07. 2. FDA approves larotrectinib for solid tumors with NTRK gene fusions. FDA, November 26, 2018. Accessed November 24, 2024. https://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntr...
It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company...